Sodium-glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells.

Miwa Morita, Keizo Kanasaki

Journal: Diabetes & metabolism 2021;46(5):353-361

PMID: 32891754

Full Text on Elsevier Science View on PubMed

Abstract

Inhibitors of sodium-glucose cotransporter 2 (SGLT2) have undoubtedly shifted the paradigm for diabetes medicine and research and, especially, diabetic kidney disease (DKD). The pharmacological action of SGLT2 inhibitors is simply the release of glucose into urine; however, precisely how SGLT2 inhibitors contribute to the health of those with diabetes has still not been completely elucidated. Towards this end, the present review provides a novel insight into the action of SGLT2 inhibitors by highlighting a neglected fuel-burning system found in proximal tubular cells-'glycolysis'. In addition, exploring the details of the molecular mechanisms and clinical biomarkers of the organ protection conferred by SGLT2 inhibitors is now required to prepare for the next stage of clinical diabetes medicine-the 'post-SGLT2 inhibitor era'.

Address: Department of Internal Medicine 1, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo 693-8501, Japan.; Department of Internal Medicine 1, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo 693-8501, Japan; Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan. Electronic address: [email protected].

DOI: 10.1016/j.diabet.2020.06.005

Link outs

Free resources

Medical:

https://medlineplus.gov/diabetickidneyproblems.htm...

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-3588

Subscription / membership required

Full Text Sources:

MeSH Terms: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glucose, Glycolysis, Humans, Kidney Tubules, Proximal, Renal Reabsorption, Sodium-Glucose Transporter 2 Inhibitors